来自官方财务报表的收入、利润与现金流历史。
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It produces, develops, and markets various branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company also offers products in the therapeutic areas of cardiovascular, diabetology, asthama, pediatrics, central nervous system, gastro-intestinal, anti-infectives, anti-TB, cephalosporins, and nonsteroidal anti-inflammatory drug therapies.
| 利润表 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| 总收入 | ₹274.9B | ₹221.9B | ₹196.6B | ₹162.7B |
| 毛利 | ₹193.8B | ₹147.4B | ₹125.1B | ₹90.1B |
| 营业利润（EBIT） | ₹68.2B | ₹43.5B | ₹28.0B | ₹8.9B |
| 净利 | ₹53.3B | ₹32.8B | ₹19.1B | ₹4.3B |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 LUPIN 交互式查看器。 /companies/us/LUPIN
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms